The problem. Artemisinin is the frontline antimalarial, but it was sourced from a plant (Artemisia annua) with volatile supply and price. Could you engineer a microbe to make it, the proof that synthetic biology yields products, not just papers?

The idea. Ro et al. engineered Saccharomyces cerevisiae to produce artemisinic acid, a precursor a few chemical steps from artemisinin. They up-regulated the yeast mevalonate pathway to flood the cell with the isoprenoid building block (FPP), expressed amorphadiene synthase to cyclize it into the artemisinin scaffold, and, the linchpin, identified and expressed a novel cytochrome P450 (CYP71AV1) from A. annua that oxidizes amorphadiene to artemisinic acid, which the yeast conveniently secretes. It’s a masterclass in metabolic engineering: redirect flux, add the committed step, add the tailoring enzyme.

Why it matters. This is the origin story behind Amyris and the later semisynthetic-artemisinin program, and it’s the paper any positioning argument about synbio’s commercial value has to reckon with. It grounds the abstract promise in one concrete, high-stakes molecule.

Verdict. A genuine landmark, and the most instructive part is what came after the paper. Getting from artemisinic acid to cost-competitive drug took roughly another decade, large public/philanthropic investment, and ultimately ran into the economics of cheap plant-derived supply. The honest lesson for a modern tooling pitch: the science was necessary but not sufficient; scale-up, economics, and timelines dominate, and it’s exactly those later stages where today’s design models and automation would most change the math.